Abstract Book

S900

ESTRO 37

Dolnoslaski Rejestr Nowotworow, Wrocław, Poland 4 Lower Silesian Oncology Center, Clinic of Radiation Oncology, Wrocław, Poland 5 Lower Silesian Oncology Center, Gynaecological Oncology Clinic, Wrocław, Poland Purpose or Objective Poland is ranked among the countries with medium cervical cancer incidence (around 3000-3500 / year) and with a low 5-year overall survival rate (OS) - 55.2%. In 2006 Poland introduced the Population-Based Cervical Cancer Prevention and Early Detection Program for women aged 25-59, in which a cytology test performed every 3 years serves as the screening test. The aim of the study was to analyze an impact of the screening program on the incidence and survival rates of women residing in Lower Silesia Province (Poland). Material and Methods 3298 cases of cervical cancer diagnosed in Lower Silesia Province recorded in 2005-2014 and 5-year OS of 3,586 patients treated in the years 2000-2010 were analyzed, respectively. Epidemiological data were obtained from the Lower Silesian Cancer Registry in Wroclaw. In order to exclude the effect of age on the 5-year OS relative survival values based on life expectancy tables were calculated. Statistical calculations were performed in Microsoft Excel using the Chi-square test with Yates correction. Results In 2005-2014, 2563 new cases of invasive cervical cancer (C53) and 735 new cases of preinvasive cancer (D06) were registered. In the analyzed period, incidence of C53 decreased by 6 cases per year and incidence of D06 increased by 4 cases per year. The observed changes were especially related to the screening population. Tab. 1. 5-year relative OS Lower Silesian cervical cancer patients in 2000-2010.

Conclusion Despite the small screening test population coverage (21%) in the Lower Silesian Province (this low coverage rate is similar in other parts of Poland), the decline in incidence of C53 and the increase in D06 were observed (Tab. 2). In women covered by screening in years 2006 – 2014, D06 accounted for 20-43% of all cases of cervical cancer, while in women above 60 years, only 3-11% (P <0.0001). In the study group we observed a steady increase in the percentage of 5-year OS. Among patients treated between 2000-2004, this proportion was 55.1%, 60.5% in 2005-2009 and 70.5% in 2010. Comparing with the European data, more than 70% of OS was achieved according to EUROCARE-5 in 2000-2007 only in eight European countries. In conclusion, the introduction of screening tests had a significant positive impact on the population of Lower Silesian women, despite the low percentage of the population covered by this program. Further action should be directed towards increasing women's awareness so that they can participate in the screening program. EP-1677 Failure to publish Radiotherapy Clinical Trials results: Is the number of participants relevant? J. Perez-Alija 1 , P. Gallego 1 , I. Linares 2 , E. Ambroa 3 , A. Pedro 4 1 Hospital de la Santa Creu i Sant Pau, Medical Physics, Barcelona, Spain 2 Institut Català d'Oncologia, Radiation Oncology Department, L'Hospitalet de Llobregat, Spain 3 Consorci Sanitari de Terrasa, Radiation Oncology Department, Terrasa, Spain 4 Hospital de la Santa Creu i Sant Pau, Radiation Oncology, Barcelona, Spain Purpose or Objective To determine the rate of non-publication of interventional phase 3&4 clinical trials in radiotherapy. To compare publication rates by number of trial participants. Our hypothesis is that rates of publication would rise significantly as soon as two different institutions are participating in the trial. Material and Methods A query on ClinicalTrials.gov for completed trials in radiotherapy was conducted. We allowed a minimum of 24 months for editorial process until the trial was finally published in a peer-reviewed journal (PRJ). We compare publications rates in a PRJ between trials grouped by number of participants. Results Overall, 387 clinical trials met the criteria for searching a publication in a PRJ. A total of 171 (44.2%) remained unpublished. When the trial was conducted by only one institution rates of non-publication increased up to 58.4%. When trials had more than one participant, non- publication rates decreased significantly (for more than 50 participants, only 12% of trials did not published their results). Conclusion All medical evidence should be both published and

In addition, the beneficial effect of the program was a constant increase in the percentage of 5-year relative OS among women with cervical cancer (C53 and D06). This percentage increased from 55.1% in 2000-2004 to 60.5% in 2005-2009, and in 2010 it reached 70.8% (Tab 1) (p <0.00001). Table 2. The number of cases of C53 and D06 in the Lower Silesian Province in 2005-2014 with the division into age groups.